Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma
- PMID: 22878374
- PMCID: PMC3464773
- DOI: 10.1038/bjc.2012.354
Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma
Abstract
Background: Inflammation-based prognostic scores including the Glasgow Prognostic Score (GPS), neutrophil to lymphocyte ratio (NLR), and Prognostic Nutritional Index (PNI) are associated with survival in patients with hepatocellular carcinoma (HCC). The aim of this study was to investigate the prognostic value of these inflammation-based prognostic scores in patients with HCC.
Methods: In total, 150 patients with newly diagnosed HCC were prospectively evaluated. Patients were divided according to the GPS, modified GPS, NLR, platelet to lymphocyte ratio (PLR), Prognostic Index (PI), and PNI. The area under the receiver operating characteristics curve (AUC) was calculated to compare the predictive ability of each of the scoring systems. A univariate and multivariate analysis were performed to identify the clinicopathological variables associated with overall survival.
Results: The GPS consistently had a higher AUC value at 6 months (0.768), 12 months (0.787), and 24 months (0.758) in comparison with other inflammation-based prognostic scores. A multivariate analysis showed that the GPS was independently associated with overall survival.
Conclusion: This study demonstrates that the GPS, an inflammation-based prognostic score, is an independent marker of poor prognosis in patients with HCC and is superior to the other inflammation-based prognostic scores in terms of prognostic ability.
© 2012 Cancer Research UK
Figures


References
-
- Argiles JM, Busquets S, Lopez-Soriano FJ (2003) Cytokines in the pathogenesis of cancer cachexia. Curr Opin Clin Nutr Metab Care 6: 401–406 - PubMed
-
- Chen TM, Lin CC, Huang PT, Wen CF (2012) Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation. J Gastroenterol Hepatol 27: 553–561 - PubMed
-
- Cho YK, Chung JW, Kim JK, Ahn YS, Kim MY, Park YO, Kim WT, Byun JH (2008) Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Cancer 112: 352–361 - PubMed
-
- Clarke SJ, Chua M, Moore M, Kao S, Phan V, Tan C, Charles K, McMillan DC (2011) Use of inflammatory markers to guide cancer treatment. Clin Pharmacol Ther 90: 475–478 - PubMed
-
- European Association for the Study of The Liver and European Organisation for Research and Treatment of Cancer (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56: 908–943 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials